Acute respiratory distress syndrome (ARDS) is a heterogeneous cause of respiratory failure
that has a rapid onset, a high mortality rate, and for which there is no effective …

Simple Summary Treatments for coronavirus disease-2019 (COVID-19) have utilized a
variety of medications, including antivirals, immunomodulators, and other therapeutics such …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has been a serious threat to
global health for nearly 3 years. In addition to pulmonary complications, liver injury is not …

Introduction The European Medicines Agency (EMA) and the United States Food and Drug
Administration (FDA) announced conditions for using recombinant human interleukin-1 …

Abstract Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerging evidence indicates that …

Introduction COVID-19 is associated to an increased risk of thrombosis, as a result of a
complex process that involves the activation of vascular and circulating cells, the release of …

Nowadays, people have relaxed their vigilance against COVID-19 due to its declining
infection numbers and attenuated virulence. However, COVID-19 still needs to be concern …

We read with great interest that biologic medications might be a promising therapeutic
option in COVID-19. 1 Neutralizing monoclonal antibodies such as regdanvimab can reduce …

Objective To evaluate the safety of canakinumab using real-world data in patients with
systemic juvenile idiopathic arthritis (sJIA) and autoinflammatory diseases (AID). Research …

Background Increasing evidence indicating that coronavirus disease 2019 (COVID-19)
increased the incidence and related risks of pericarditis and whether COVID-19 vaccine is …